Investors & Media

Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema

– OASIS-HAE is the registrational study in Ionis’ donidalorsen Phase 3 clinical program and further expands Ionis’ late-stage pipeline – Donidalorsen is one of Ionis’ wholly owned medicines the company plans to commercialize CARLSBAD, Calif. , Nov. 18, 2021 /PRNewswire/ — Ionis Pharmaceuticals,

Read more
You are now leaving to visit